Evidence map›Paper›PMID 37597051›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2023

The impact of COVID on bacterial sepsis.

Sophia Dar, Daniel Erickson, Claudia Manca, Tara Lozy, Elena Shashkina, Milena Kordalewska, Jose R Mediavilla, Liang Chen, Albert Rojtman, Barry N Kreiswirth

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophia DarHackensack Meridian School of Medicine, Nutley, NJ, 07110, USA.
Daniel EricksonHackensack Meridian School of Medicine, Nutley, NJ, 07110, USA.
Claudia MancaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Tara LozyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Elena ShashkinaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Milena KordalewskaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Jose R MediavillaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Liang ChenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
Albert RojtmanJersey Shore University Medical Center, Neptune, NJ, 07753, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA. barry.kreiswirth@hmh-cdi.org.ORCID http://orcid.org/0000-0002-0243-131X

Funding

Merck MISP 60453
6 · The paper itself

Abstract

purposeTo identify the predictors of morbidity and mortality in matched COVID-19 positive and negative patients who were septic with Gram positive or Gram negative infections.

methodsWe conducted a retrospective review, from March to October 2020, of matched septic patients at five Hackensack Meridian Health hospitals who had bacteremia with Staphylococcus aureus, Klebsiella pneumoniae or Escherichia coli with and without COVID-19. We extracted patient demographics, comorbidities and clinical outcomes data using ICD-10 codes. Bacterial isolates were compared by whole genome sequencing analysis. Multivariate logistic regression was used to analyze independent predictors of morbidity and mortality.

resultsA total of 208 patients were grouped by positive bloodstream infection (BSI) with COVID-19 (n = 104) and without COVID-19 (n = 104). Most patients were over age 50 (90% vs. 89%) and Caucasian (78% vs. 86%). Inpatient mortality was higher in patients with COVID-19 for both GP (35% vs. 8%, p < 0.05) and GN (28% vs. 10%, p < 0.05) BSIs. Patients with Gram positive (GP) BSIs had a significant increase in mortality risk (OR 4.5, CI 1.4-14.5, p < 0.05) in contrast to those with Gram negative (GN) infections (OR 0.4, CI 0.4-4.0, p = 0.4).

conclusionConcurrent COVID-19 infection is associated with a significant increase in morbidity and mortality in patients with GP and GN BSIs. Patients with S. aureus BSIs with COVID-19 are more likely to develop shock and respiratory failure and have higher rates and odds of mortality than those without COVID-19. These findings provide an essential insight into the care of these patients, especially those co-infected with Staphylococcus aureus.

Indexed as

BacteremiaCOVID-19SepsisStaphylococcal InfectionsEscherichia coliHumansInpatientsMiddle AgedStaphylococcus aureusBacteremiaCOVID-19Staphylococcus aureus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.